




Instance: composition-en-11132a32e01a148874091fa148cdfa6e
InstanceOf: CompositionUvEpi
Title: "Composition for abiraterone Package Leaflet"
Description:  "Composition for abiraterone Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpede3ebc50fadfc44dda6a4212b37eb57)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - abiraterone"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Abiraterone Mylan is and what it is used for </li>
<li>What you need to know before you take Abiraterone Mylan </li>
<li>How to take Abiraterone Mylan </li>
<li>Possible side effects </li>
<li>How to store Abiraterone Mylan </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What abiraterone is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What abiraterone is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Abiraterone Mylan contains a medicine called abiraterone acetate. It is used to treat prostate cancer in 
adult men that has spread to other parts of the body. Abiraterone Mylan stops your body from making 
testosterone; this can slow the growth of prostate cancer. </p>
<p>When Abiraterone Mylan is prescribed for the early stage of disease where it is still responding to 
hormone therapy, it is used with a treatment that lowers testosterone (androgen deprivation therapy). </p>
<p>When you take this medicine your doctor will also prescribe another medicine called prednisone or 
prednisolone. This is to lower your chances of getting high blood pressure, having too much water in 
your body (fluid retention), or having reduced levels of a chemical known as potassium in your blood. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take abiraterone"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take abiraterone"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Abiraterone Mylan 
- if you are allergic to abiraterone acetate or any of the other ingredients of this medicine (listed 
in section 6). 
- if you are a woman, especially if pregnant. Abiraterone Mylan is for use in male patients only. 
- if you have severe liver damage. 
- in combination with Ra-223 (which is used to treat prostate cancer). </p>
<p>Do not take this medicine if any of the above apply to you. If you are not sure, talk to your doctor or 
pharmacist before taking this medicine. </p>
<p>Warnings and precautions 
Talk to your doctor or pharmacist before taking this medicine:</p>
<ul>
<li>if you have liver problems. </li>
<li>if you have been told you have high blood pressure or heart failure or low blood potassium (low 
blood potassium may increase the risk of heart rhythm problems). </li>
<li>if you have had other heart or blood vessel problems. </li>
<li>if you have an irregular or rapid heart rate. </li>
<li>if you have shortness of breath. </li>
<li>if you have gained weight rapidly. </li>
<li>if you have swelling in the feet, ankles, or legs. </li>
<li>if you have taken a medicine known as ketoconazole in the past for prostate cancer. </li>
<li>about the need to take this medicine with prednisone or prednisolone. </li>
<li>about possible effects on your bones. </li>
<li>if you have high blood sugar. </li>
</ul>
<p>Tell your doctor if you have been told you have any heart or blood vessel conditions, including heart 
rhythm problems (arrhythmia), or are being treated with medicines for these conditions. </p>
<p>Tell your doctor if you have yellowing of the skin or eyes, darkening of the urine, or severe nausea or 
vomiting, as these could be signs or symptoms of liver problems. Rarely, failure of the liver to 
function (called acute liver failure) may occur, which can lead to death. </p>
<p>Decrease in red blood cells, reduced sex drive (libido), muscle weakness and/or muscle pain may 
occur. </p>
<p>Abiraterone Mylan must not be given in combination with Ra-223 due to a possible increase in the 
risk of bone fracture or death. </p>
<p>If you plan to take Ra-223 following treatment with Abiraterone Mylan and prednisone/prednisolone, 
you must wait 5 days before starting treatment with Ra-223. If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before taking this 
medicine. </p>
<p>Blood monitoring 
Abiraterone Mylan may affect your liver, and you may not have any symptoms. When you are taking 
this medicine, your doctor will check your blood periodically to look for any effects on your liver. </p>
<p>Children and adolescents 
This medicine is not for use in children and adolescents. If Abiraterone Mylan is accidentally ingested 
by a child or adolescent, go to the hospital immediately and take the package leaflet with you to show 
to the emergency doctor. </p>
<p>Other medicines and Abiraterone Mylan 
Ask your doctor or pharmacist for advice before taking any medicine. </p>
<p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. This is important because Abiraterone Mylan may increase the effects of a number of 
medicines including heart medicines, tranquilisers, some medicines for diabetes, herbal medicines 
(e.g., St John s wort) and others. Your doctor may want to change the dose of these medicines. Also, 
some medicines may increase or decrease the effects of Abiraterone Mylan. This may lead to side 
effects or to Abiraterone Mylan not working as well as it should. </p>
<p>Androgen deprivation treatment may increase the risk of heart rhythm problems. Tell your doctor if 
you are receiving medicine:</p>
<ul>
<li>used to treat heart rhythm problems (e.g. quinidine, procainamide, amiodarone and sotalol). </li>
<li>known to increase the risk of heart rhythm problems [e.g. methadone (used for pain relief and 
part of drug addiction detoxification), moxifloxacin (an antibiotic), antipsychotics (used for 
serious mental illnesses)]. </li>
</ul>
<p>Tell your doctor if you are taking any of the medicines listed above. 
Abiraterone Mylan with food 
- This medicine must not be taken with food (see section 3  How to take Abiraterone Mylan ). 
- Taking Abiraterone Mylan with food may cause side effects. </p>
<p>Pregnancy and breast-feeding 
Abiraterone Mylan is not for use in women. 
- This medicine may cause harm to the unborn child if it is taken by women who are 
pregnant. 
- Women who are pregnant or who may be pregnant should wear gloves if they need to 
touch or handle Abiraterone Mylan. 
- If you are having sex with a woman who can become pregnant, use a condom and another 
effective birth control method. 
- If you are having sex with a pregnant woman, use a condom to protect the unborn child. </p>
<p>Driving and using machines 
This medicine is not likely to affect your being able to drive and use any tools or machines. </p>
<p>Abiraterone Mylan contains lactose and sodium 
- This medicine contains lactose (a type of sugar). If you have been told by your doctor that you 
have an intolerance to some sugars, contact your doctor before taking this medicine. 
- This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 
 sodium-free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take abiraterone"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take abiraterone"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist 
if you are not sure. </p>
<p>How much to take 
The recommended dose is 1000 mg (two 500 mg tablets or one 1000 mg tablet) once a day. </p>
<p>Taking this medicine 
- Take this medicine by mouth. 
- Do not take Abiraterone Mylan with food. Taking Abiraterone Mylan with food may 
cause more of the medicine to be absorbed by the body than is needed and this may cause 
side effects. 
- Take Abiraterone Mylan tablets as a single dose once daily on an empty stomach. 
Abiraterone Mylan must be taken at least two hours after eating and food must not be 
eaten for at least one hour after taking Abiraterone Mylan. (see section 2,  Abiraterone 
Mylan with food ). 
- Swallow the tablets with water. 
- For 500 mg: Do not break the tablets. 
- For 1000 mg: Tablets can be divided to make it easier to swallow. 
- Abiraterone Mylan is taken with a medicine called prednisone or prednisolone. Take the 
prednisone or prednisolone exactly as your doctor has told you. 
- You need to take prednisone or prednisolone every day while you are taking Abiraterone 
Mylan. 
- The amount of prednisone or prednisolone you take may need to change if you have a medical 
emergency. Your doctor will tell you if you need to change the amount of prednisone or 
prednisolone you take. Do not stop taking prednisone or prednisolone unless your doctor tells 
you to. </p>
<p>Your doctor may also prescribe other medicines while you are taking Abiraterone Mylan and 
prednisone or prednisolone. </p>
<p>If you take more Abiraterone Mylan than you should 
If you take more than you should, talk to your doctor or go to a hospital immediately. </p>
<p>If you forget to take Abiraterone Mylan 
- If you forget to take Abiraterone Mylan or prednisone or prednisolone, take your usual dose the 
following day. 
- If you forget to take Abiraterone Mylan or prednisone or prednisolone for more than one day, 
talk to your doctor without delay. </p>
<p>If you stop taking Abiraterone Mylan 
Do not stop taking Abiraterone Mylan or prednisone or prednisolone unless your doctor tells you to. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Stop taking Abiraterone Mylan and see a doctor immediately if you notice any of the following:</p>
<ul>
<li>Muscle weakness, muscle twitches or a pounding heart beat (palpitations). These may be signs 
that the level of potassium in your blood is low. </li>
</ul>
<p>Other side effects include: 
Very common (may affect more than 1 in 10 people): 
Fluid in your legs or feet, low blood potassium, liver function test increases, high blood pressure, 
urinary tract infection, diarrhoea. </p>
<p>Common (may affect up to 1 in 10 people): 
High fat levels in your blood, chest pain, irregular heart beat (atrial fibrillation), heart failure, rapid 
heart rate, severe infections called sepsis, bone fractures, indigestion, blood in urine, rash. </p>
<p>Uncommon (may affect up to 1 in 100 people): 
Adrenal gland problems (related to salt and water problems), abnormal heart rhythm (arrhythmia), 
muscle weakness and/or muscle pain. </p>
<p>Rare (may affect up to 1 in 1,000 people): 
Lung irritation (also called allergic alveolitis). 
Failure of the liver to function (also called acute liver failure). </p>
<p>Not known (frequency cannot be estimated from the available data): 
Heart attack, changes in ECG - electrocardiogram (QT prolongation), and serious allergic reactions 
with difficulty swallowing or breathing, swollen face, lips, tongue or throat, or an itchy rash. </p>
<p>Bone loss may occur in men treated for prostate cancer. Abiraterone in combination with prednisone 
or prednisolone may increase bone loss. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store abiraterone"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store abiraterone"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. 
Do not use this medicine after the expiry date which is stated on the carton, blister and bottle after 
EXP. The expiry date refers to the last day of that month. </p>
<p>This medicinal product does not require any special storage conditions. 
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist 
how to throw away medicines you no longer use. These measures will help to protect the 
environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Abiraterone Mylan contains </p>
<p>The active substance is abiraterone acetate. Each film-coated tablet contains 500 mg or 1000 mg 
abiraterone acetate. 
The other ingredients are: 
Tablet core: croscarmellose sodium (E468), sodium laurilsulfate, povidone, microcrystalline cellulose 
(E460), lactose monohydrate, silica colloidal anhydrous (E551) and magnesium stearate (E470b). 
Film-coat: poly(vinyl alcohol), titanium dioxide (E171), macrogol (E1521) and talc (E553b). 
Additionally, the 500 mg tablets contain red iron oxide (E172) and black iron oxide (E172). 
See section 2  Abiraterone Mylan contains lactose and sodium . </p>
<p>What Abiraterone Mylan looks like and contents of the pack </p>
<p>Abiraterone Mylan 500 mg film-coated tablets are brown, oval-shaped (19 mm long x 10 mm 
wide), with  500  debossed on one side and available in blister packs containing 56, 60 tablets and in 
perforated unit dose blister packs containing, 56 x 1, 60 x 1 tablets. </p>
<p>Abiraterone Mylan 1000 mg film-coated tablets are white to off-white, oval-shaped (23 mm long x 
11 mm wide), with a break line on one side and plain on the other side  available in bottles containing 
28 or 30 tablets and also available in blister packs containing 28, 30 tablets and in perforated unit dose 
blister packs containing, 28 x 1, 30 x 1 tablets. The bottle also contains an oxygen absorbing canister. 
Do not swallow the oxygen absorbing canister as this may be harmful to your health. </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder 
Mylan Ireland Limited 
Unit 35/36 Grange Parade, 
Baldoyle Industrial Estate 
Dublin 13, 
Ireland. </p>
<p>Manufacturer 
Remedica Ltd., 
Aharnon Street, 
Limassol Industrial Estate, 
3056 Limassol, 
Cyprus </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: 
Belgi /Belgique/Belgien 
Viatris 
T l/Tel: + 32 (0)2 658 61 Lietuva 
Mylan Healthcare UAB 
Tel: +370 5 205 1  </p>
<p>: +359 2 44 55 Luxembourg/Luxemburg 
Viatris 
Tel: + 32 (0)2 658 61 (Belgique/Belgien) </p>
<p>esk  republika 
Viatris CZ.s.r.o. 
Tel: + 420 222 004 Magyarorsz g 
Mylan EPD Kft 
Tel: + 36 1 465 2Danmark 
Viatris ApS 
Tlf: +45 28 11 69 Malta 
V.J. Salomone Pharma Ltd 
Tel: + 356 21 22 01 Deutschland 
Viatris Healthcare GmbH 
Tel: +49 800 0700 Nederland 
Mylan BV 
Tel: +31 (0)20 426 3Eesti 
BGP Products Switzerland GmbH Eesti 
filiaal 
Tel: + 372 6363 Norge 
Viatris AS 
Tfl: + 47 66 75 33 <br />
Generics Pharma Hellas <br />
 : +30 210 993 6 sterreich 
Arcana Arzneimittel GmbH 
Tel: +43 1 416 2Espa a 
Viatris Pharmaceuticals, S.L.U. 
Tel: + 34 900 102 Polska 
Mylan Healthcare Sp. z. o.o. 
Tel: + 48 22 546 64 France 
Viatris Sant<br />
T l: +33 4 37 25 75 Portugal 
Mylan, Lda. 
Tel: + 351 214 127 Hrvatska 
Mylan Hrvatska d.o.o. 
Tel: +385 1 23 50 Rom nia 
BGP Products SRL 
Tel: +40 372 579 Ireland 
Mylan Ireland Limited 
Tel: +353 1 8711Slovenija 
Viatris d.o.o.<br />
Tel: + 386 1 23 63  sland 
Icepharma hf 
S mi: +354 540 8Slovensk  republika 
Viatris Slovakia s.r.o. 
Tel: +421 2 32 199 Italia 
Mylan Italia S.r.l. 
Tel: + 39 02 612 46Suomi/Finland 
Viatris Oy 
Puh/Tel: +358 20 720 9<br />
Varnavas Hadjipanayis Ltd 
 : +357 2220 7Sverige 
Viatris AB 
Tel: + 46 (0)8 630 19 Latvija 
Mylan Healthcare SIA 
Tel: +371 676 055 United Kingdom (Northern Ireland) 
Mylan IRE Healthcare Limited 
Tel: +353 18711This leaflet was last revised in </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-11132a32e01a148874091fa148cdfa6e
InstanceOf: CompositionUvEpi
Title: "Composition for abiraterone Package Leaflet"
Description:  "Composition for abiraterone Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpede3ebc50fadfc44dda6a4212b37eb57)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - abiraterone"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse  </li>
<li>Det skal du vide, før du begynder at tage Abiraterone Mylan  </li>
<li>Sådan skal du tage Abiraterone Mylan </li>
<li>Bivirkninger  </li>
<li>Opbevaring af Abiraterone Mylan  </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What abiraterone is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What abiraterone is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Abiraterone Mylan indeholder lægemidlet abirateronacetat. Det anvendes til at behandle voksne mænd 
med prostatacancer, som har spredt sig til andre dele af kroppen. Abiraterone Mylan hindrer kroppen i 
at fremstille testosteron og kan derved nedsætte væksten af prostatacancer. </p>
<p>Når Abiraterone Mylan anvendes i sygdommens tidlige fase, hvor den stadig reagerer på 
hormonbehandling, anvendes det sammen med en behandling, der nedsætter dannelsen af testosteron 
(androgen deprivationsbehandling). </p>
<p>Mens du er i behandling med dette lægemiddel, vil din læge også ordinere enten prednison eller 
prednisolon til dig. Derved nedsættes risikoen for, at du får højt blodtryk, for meget væske i kroppen 
(væskeretention) eller nedsat indhold af mineralet kalium i blodet. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take abiraterone"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take abiraterone"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Abiraterone Mylan 
- hvis du er allergisk over for abirateronacetat eller et af de øvrige indholdsstoffer i denne 
medicin (angivet i punkt 6). 
- hvis du er en kvinde, og især hvis du er gravid. Abiraterone Mylan er udelukkende beregnet til 
brug hos mandlige patienter. 
- hvis du har svære leverskader. 
- i kombination med Ra-223 (som anvendes til behandling af prostatacancer). </p>
<p>Tag ikke dette lægemiddel, hvis noget af dette gælder for dig. Hvis du er i tvivl, så spørg din læge eller 
apotekspersonalet, inden du tager dette lægemiddel.  </p>
<p>Advarsler og forsigtighedsregler<br />
Kontakt lægen eller apotekspersonalet, før du tager dette lægemiddel:</p>
<ul>
<li>hvis du har leverproblemer. </li>
<li>hvis du har fået at vide, at du har højt blodtryk eller hjertesvigt eller lavt indhold af kalium i 
blodet (lavt indhold af kalium i blodet kan øge risikoen for problemer med hjerterytmen). </li>
<li>hvis du har haft andre problemer med hjerte eller blodkar. </li>
<li>hvis du har en uregelmæssig eller hurtig puls. </li>
<li>hvis du er kortåndet. </li>
<li>hvis du har taget hurtigt på i vægt. </li>
<li>hvis du har hævede fødder, ankler eller ben. </li>
<li>hvis du tidligere har taget ketoconazol mod prostatacancer. </li>
<li>om nødvendigheden af at tage dette lægemiddel sammen med prednison eller prednisolon. </li>
<li>om hvordan lægemidlet kan påvirke knoglerne. </li>
<li>hvis du har højt blodsukker. </li>
</ul>
<p>Fortæl det til lægen, hvis du har fået at vide, at du har sygdomme, der vedrører hjertet eller 
blodkarrene, herunder problemer med hjerterytmen (arytmi), eller hvis du får lægemidler for sådanne 
sygdomme. </p>
<p>Fortæl det til lægen, hvis du får gulfarvning af huden eller øjnene, mørk urin eller svær kvalme eller 
opkastning, eftersom dette kan være tegn eller symptomer på leverproblemer. I sjældne tilfælde kan 
leveren holde op med at fungere (dette kaldes akut leversvigt), hvilket kan være dødeligt. </p>
<p>Nedsat antal røde blodlegemer, nedsat sexlyst (libido) samt muskelsvaghed og/eller muskelsmerter 
kan forekomme. </p>
<p>Abiraterone Mylan må ikke gives i kombination med Ra-223 på grund af en mulig forøgelse af 
risikoen for knoglebrud eller dødsfald. </p>
<p>Hvis du planlægger at tage Ra-223 efter behandling med Abiraterone Mylan og 
prednison/prednisolon, skal du vente 5 dage, før du starter behandling med Ra-223. Spørg lægen eller på apoteket, før du tager dette lægemiddel, hvis du er usikker på, om noget af dette 
gælder for dig. </p>
<p>Blodprøvekontrol 
Abiraterone Mylan kan påvirke leveren, uden at du får symptomer. Når du tager dette lægemiddel, 
skal du have taget jævnlige blodprøver hos lægen for at få kontrolleret, om medicinen påvirker din 
lever. </p>
<p>Børn og unge 
Dette lægemiddel er ikke beregnet til børn og unge. Hvis et barn eller en ung person ved et uheld 
kommer til at tage Abiraterone Mylan, skal I straks tage på hospitalet og medbringe indlægssedlen, så 
I kan vise den til lægen på skadestuen. </p>
<p>Brug af anden medicin sammen med Abiraterone Mylan 
Spørg din læge eller apoteket til råds, før du tager nogen form for medicin. </p>
<p>Fortæl altid lægen eller apotekspersonalet, hvis du tager anden medicin eller har gjort det for nylig. 
Det er vigtigt, fordi Abiraterone Mylan kan forstærke virkningen af en række lægemidler, herunder 
blandt andet hjertemedicin, beroligende midler, visse lægemidler mod diabetes, naturlægemidler 
(f.eks. perikon) og anden medicin. Din læge vil måske ændre dosis af disse lægemidler. Desuden kan 
nogle lægemidler forstærke eller nedsætte virkningen af Abiraterone Mylan. Det kan medføre 
bivirkninger eller resultere i, at Abiraterone Mylan ikke virker så godt, som det skal. </p>
<p>Androgen deprivationsbehandling kan øge risikoen for problemer med hjerterytmen. Fortæl det til 
lægen, hvis du får medicin, som:</p>
<ul>
<li>bruges til at behandle problemer med hjerterytmen (f.eks. kinidin, procainamid, amiodaron og 
sotalol). </li>
<li>vides at øge risikoen for problemer med hjerterytmen [f.eks. metadon (som anvendes til 
smertelindring samt i forbindelse med afvænning ved stofmisbrug), moxifloxacin (et 
antibiotikum), antipsykotika (som anvendes til alvorlige psykiske lidelser)]. </li>
</ul>
<p>Fortæl det til din læge, hvis du tager nogen af de ovenstående lægemidler. </p>
<p>Brug af Abiraterone Mylan sammen med mad 
- Dette lægemiddel må ikke tages sammen med mad (se ”Sådan skal du tage Abiraterone Mylan” 
under punkt 3). 
- Indtagelse af Abiraterone Mylan sammen med mad kan give bivirkninger. </p>
<p>Graviditet og amning 
Abiraterone Mylan er ikke beregnet til kvinder. 
- Dette lægemiddel kan skade fosteret, hvis det tages af kvinder, som er gravide.<br />
- Kvinder, som er gravide, eller kvinder, som måske kan være gravide, skal anvende 
handsker, hvis det er nødvendigt, at de rører ved eller håndterer Abiraterone Mylan. 
- Brug kondom og en anden sikker præventionsmetode hvis du dyrker sex med en kvinde, 
som kan blive gravid. 
- Brug kondom for at beskytte fosteret, hvis du har sex med en gravid kvinde. </p>
<p>Trafik- og arbejdssikkerhed 
Dette lægemiddel påvirker sandsynligvis ikke arbejdssikkerheden eller evnen til at færdes i trafikken. </p>
<p>Abiraterone Mylan indeholder lactose og natrium 
- Dette lægemiddel indeholder lactose (sukkerart). Kontakt lægen, før du tager denne medicin, 
hvis lægen har fortalt dig, at du ikke tåler visse sukkerarter. 
- Dette lægemiddel indeholder mindre end 1 mmol natrium (23 mg) pr. tablet, dvs. det er i det 
væsentlige natriumfrit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take abiraterone"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take abiraterone"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen eller 
apotekspersonalet. </p>
<p>Hvor meget 
Den anbefalede dosis er 1.000 mg (to 500 mg tabletter eller én 1000 mg tablet) én gang dagligt. </p>
<p>Sådan skal du tage medicinen 
- Dette lægemiddel skal indtages gennem munden. 
- Abiraterone Mylan må ikke tages sammen med mad. Hvis du tager Abiraterone Mylan 
sammen med mad, kan det ske, at mere af lægemidlet optages i kroppen, end det skal, og 
det kan give bivirkninger. 
- Tag Abiraterone Mylan-tabletterne som en enkelt dosis én gang om dagen på tom mave. 
Abiraterone Mylan skal tages mindst 2 timer efter et måltid, og du må ikke spise noget i 
mindst 1 time efter at have taget Abiraterone Mylan (se ”Brug af Abiraterone Mylan 
sammen med mad” under punkt 2). 
- Synk tabletterne med vand. 
- Ved 500 mg: Tabletterne må ikke deles. 
- Ved 1000 mg: Tabletter kan todeles for at lette synkning. 
- Abiraterone Mylan skal tages sammen med lægemidlet prednison eller prednisolon. Tag 
prednison eller prednisolon nøjagtigt efter lægens anvisning. 
- Du skal tage prednison eller prednisolon dagligt, mens du tager Abiraterone Mylan. 
- Den mængde prednison eller prednisolon, som du får, skal måske ændres hvis der opstår en akut 
medicinsk tilstand. Din læge fortæller dig, hvis der skal ændres på den mængde prednison eller 
prednisolon, som du får. Hold ikke op med at tage prednison eller prednisolon, medmindre din 
læge giver dig besked på det. </p>
<p>Lægen kan også foreskrive anden medicin under din behandling med Abiraterone Mylan og prednison 
eller prednisolon. </p>
<p>Hvis du har taget for meget Abiraterone Mylan 
Kontakt straks lægen eller tag på skadestuen, hvis du har taget for mange tabletter. </p>
<p>Hvis du har glemt at tage Abiraterone Mylan 
- Hvis du glemmer at tage Abiraterone Mylan, prednison eller prednisolon, skal du tage den 
sædvanlige dosis næste dag. 
- Kontakt straks lægen, hvis du har glemt at tage Abiraterone Mylan, prednison eller prednisolon 
i mere end én dag. </p>
<p>Hvis du holder op med at tage Abiraterone Mylan 
Hold ikke op med at tage Abiraterone Mylan, medmindre din læge giver dig besked på det. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Hold op med at tage Abiraterone Mylan, og kontakt straks en læge, hvis du bemærker følgende:</p>
<ul>
<li>Muskelsvaghed, muskeltrækninger eller hjertebanken (palpitationer). Dette kan være tegn på, at 
blodets indhold af kalium er lavt. </li>
</ul>
<p>Øvrige bivirkninger omfatter: 
Meget almindelige (kan berøre flere end 1 ud af 10 patienter): 
Væske i ben eller fødder, lavt indhold af kalium i blodet, forhøjede leverfunktionsprøver, højt 
blodtryk, urinvejsinfektion, diarré. </p>
<p>Almindelige (kan berøre op til 1 ud af 10 patienter): 
Højt indhold af fedt i blodet, smerter i brystet, uregelmæssig puls (atrieflimren), hjertesvigt, hurtig 
puls, alvorlige infektioner, som kaldes blodforgiftning (sepsis), knoglebrud, mavebesvær, blod i 
urinen, udslæt. </p>
<p>Ikke almindelige (kan berøre op til 1 ud af 100 patienter): 
Binyrebarksvigt (relateret til problemer med væske- og saltbalancen), unormal hjerterytme (arytmi), 
muskelsvaghed og/eller muskelsmerter. </p>
<p>Sjældne (kan berøre op til 1 ud af 1.000 patienter): 
Lungeirritation (også kaldet allergisk alveolitis). 
Ophør af leverens funktion (også kaldet akut leversvigt). </p>
<p>Ikke kendt (hyppigheden kan ikke estimeres ud fra forhåndenværende data): 
Hjerteanfald, ændringer i elektrokardiogram (QT-forlængelse i EKG) og alvorlige allergiske 
reaktioner, med synke- eller vejrtrækningsbesvær, hævelse i ansigt, læber, tunge eller svælg eller 
kløende udslæt. </p>
<p>Knogletab kan forekomme hos mænd, der behandles for prostatacancer. Abiraterone i kombination 
med prednison eller prednisolon kan øge knogletabet. </p>
<p>Indberetning af bivirkninger 
Kontakt lægen, apotekspersonalet eller sygeplejersken, hvis du får bivirkninger, herunder bivirkninger, 
som ikke er nævnt i denne indlægsseddel. Du eller dine pårørende kan også indberette bivirkninger 
direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i Appendiks V. Ved at 
indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om sikkerheden af dette 
lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store abiraterone"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store abiraterone"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på kartonen, blisteren eller beholderen. 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen. 
Du må du ikke smide medicinrester i afløbet eller toilettet eller skraldespanden. Spørg 
apotekspersonalet, 
hvordan du skal bortskaffe medicinrester. Disse tiltag hjælper med at beskytte 
miljøet. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Abiraterone Mylan indeholder  </p>
<p>Aktivt stof: abirateron acetat. Hver filmovertrukket tablet indeholder 500 mg eller 1000 mg abirateron 
acetat. 
Øvrige indholdsstoffer:<br />
Tablettens kerne: croscarmellosenatrium (E468), natriumlaurilsulfat, povidon, mikrokrystallinsk 
cellulose (E460), lactosemonohydrat, kolloid vandfri silica (E551) og magnesiumstearat (E470b). 
Filmovertræk: poly(vinylalkohol), titandioxid (E171), macrogol (E1521) og talkum (E553b). 
Derudover indeholder 500 mg tabletterne rød jernoxid (E172) og sort jernoxid (E172). 
Se punkt 2 ”Abiraterone Mylan indeholder lactose og natrium". </p>
<p>Udseende og pakningsstørrelser for Abiraterone Mylan </p>
<p>Abiraterone Mylan 500 mg filmovertrukne tabletter er brune, ovale tabletter (19 mm lange 
x 10 mm brede), med “500” præget på den ene side. De udleveres i blisterpakninger, der indeholder 
56, 60 tabletter og i perforerede enkeltdosis blisterpakninger, der indeholder 56 x 1, 60 x 1 tabletter.  </p>
<p>Abiraterone Mylan 1000 mg filmovertrukne tabletter er hvide til offwhite, ovale tabletter (23 mm 
lange x 11 mm brede) med en delekærv på den ene side og almindelig på den anden side. De udleveres 
i beholdere med 28 eller 30 tabletter, eller i blisterpakninger med 28 eller 30 tabletter, eller i 
perforerede enkeltdosisblisterpakninger med 28 x 1 eller 30 x 1 tabletter. Beholderen indeholder også 
en iltabsorberende kanister. Slug ikke den iltabsorberende kanister, da det kan være skadeligt for dit 
helbred. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen 
Mylan Ireland Limited 
Unit 35/36 Grange Parade,<br />
Baldoyle Industrial Estate 
Dublin 13, 
Irland. </p>
<p>Fremstiller 
Remedica Ltd., 
Aharnon Street, 
Limassol Industrial Estate, 
3056 Limassol, 
Cypern </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Viatris 
Tél/Tel: + 32 (0)2 658 61<br />
Lietuva 
Viatris UAB<br />
Tel: +370 5 205 1 
България 
Майлан ЕООД 
Тел: +359 2 44 55<br />
Luxembourg/Luxemburg 
Viatris 
Tél/Tel: + 32 (0)2 658 61 (Belgique/Belgien) </p>
<p>Česká republika 
Viatris CZ.s.r.o. 
Tel: + 420 222 004<br />
Magyarország 
Viatris Healthcare Kft. 
Tel.: + 36 1 465 2Danmark 
Viatris ApS 
Tlf: +45 28 11 69<br />
Malta 
V.J. Salomone Pharma Ltd 
Tel: + 356 21 22 01<br />
Deutschland 
Viatris Healthcare GmbH 
Tel: +49 800 0700<br />
Nederland 
Mylan BV 
Tel: +31 (0)20 426 3Eesti 
Viatris OÜ<br />
Tel: + 30 2100 100<br />
Norge 
Viatris AS 
Tlf: + 47 66 75 33<br />
Ελλάδα<br />
Viatris Hellas Ltd<br />
Τηλ: +30 210 993 6410  </p>
<p>Österreich 
Arcana Arzneimittel GmbH 
Tel: +43 1 416 2 
España 
Viatris Pharmaceuticals, S.L. 
Tel: + 34 900 102<br />
Polska 
Viatris Healthcare Sp. z o.o. 
Tel: + 48 22 546 64<br />
France 
Viatris Santé 
Tél: +33 4 37 25 75<br />
Portugal 
Mylan, Lda. 
Tel: + 351 214 127<br />
Hrvatska 
Viatris Hrvatska d.o.o. 
Tel: +385 1 23 50 <br />
România 
BGP Products SRL 
Tel: +40 372 579<br />
Ireland 
Viatris Limited 
Tel: +353 1 8711Slovenija 
Viatris d.o.o. 
Tel: + 386 1 23 63<br />
Ísland 
Icepharma hf. 
Sími: +354 540 8 
Slovenská republika 
Viatris Slovakia s.r.o. 
Tel: +421 2 32 199 Italia 
Viatris Italia S.r.l. 
Tel: + 39 (0) 2 612 46 
Suomi/Finland 
Viatris Oy 
Puh/Tel: +358 20 720 9 
Κύπρος 
GPA Pharmaceuticals Ltd<br />
Τηλ: +357 22863 
Sverige 
Viatris AB<br />
Tel: + 46 (0)8 630 19<br />
Latvija 
Viatris SIA 
Tel: +371 676 055<br />
United Kingdom (Northern Ireland) 
Mylan IRE Healthcare Limited<br />
Tel: +353 18711 </p>
<p>Denne indlægsseddel blev senest ændret </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu.  </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-11132a32e01a148874091fa148cdfa6e
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for abiraterone Package Leaflet for language en"
Description: "ePI document Bundle for abiraterone Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-11132a32e01a148874091fa148cdfa6e"
* entry[0].resource = composition-en-11132a32e01a148874091fa148cdfa6e

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp11132a32e01a148874091fa148cdfa6e"
* entry[=].resource = mp11132a32e01a148874091fa148cdfa6e
                            
                    
Instance: bundlepackageleaflet-da-11132a32e01a148874091fa148cdfa6e
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for abiraterone Package Leaflet for language da"
Description: "ePI document Bundle for abiraterone Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-11132a32e01a148874091fa148cdfa6e"
* entry[0].resource = composition-da-11132a32e01a148874091fa148cdfa6e

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp11132a32e01a148874091fa148cdfa6e"
* entry[=].resource = mp11132a32e01a148874091fa148cdfa6e
                            
                    



Instance: mp11132a32e01a148874091fa148cdfa6e
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product abiraterone"
Description: "abiraterone"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/21/1571/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Abiraterone Mylan is indicated with prednisone or prednisolone for:"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "abiraterone"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: 11132a32e01a148874091fa148cdfa6eListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "abiraterone"

* status = #current
* mode = #working

* title = "List of all ePIs associated with abiraterone"

* subject = Reference(mpede3ebc50fadfc44dda6a4212b37eb57)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#abiraterone "abiraterone"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-11132a32e01a148874091fa148cdfa6e) // abiraterone en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-11132a32e01a148874091fa148cdfa6e) // abiraterone da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-11132a32e01a148874091fa148cdfa6e
InstanceOf: List

* insert 11132a32e01a148874091fa148cdfa6eListRuleset
    